ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma

Liu, Kaidong; Geng, Yiding; Wang, Linzhu; Xu, Huanhuan; Zou, Min; Li, Yawei; Zhao, Zhangxiang; Chen, Tingting; Xu, Fengyan; Sun, Liang; Wu, Shuliang*; Gu, Yunyan*哈尔滨医科大学; 1
Molecular Oncology2022-8DOI: 10.1002/1878-0261.13279
8被引4阅读
引用收藏
分享

摘要

Resistance to gemcitabine is the main challenge of chemotherapy for pancreatic ductal adenocarcinoma (PDAC). Hence, the development of a response signature to gemcitabine is essential for precision therapy of PDAC. However, existing quantitative signatures of gemcitabine are susceptible to batch effects and variations in sequencing platforms. Therefore, based on within-sample relative expression ordering of pairwise genes, we developed a transcriptome-based gemcitabine signature consisting of 28 gene pairs (28-GPS) that could predict response to gemcitabine for PDAC at the individual level. The 28-GPS was superior to previous quantitative signatures in terms of classification accuracy and prognostic performance. Resistant samples classified by 28-GPS showed poorer overall survival, higher genomic instability, lower immune infiltration, higher metabolic level and higher-fidelity DNA damage repair compared with sensitive samples. In addition, we found that gemcitabine combined with phosphoinositide 3-kinase (PI3K) inhibitor may be an alternative treatment strategy for PDAC. Single-cell analysis revealed that cancer cells in the same PDAC sample showed both the characteristics of sensitivity and resistance to gemcitabine, and the activation of the TGF beta signalling pathway could promote progression of PDAC. In brief, 28-GPS could robustly determine whether PDAC is resistant or sensitive to gemcitabine, and may be an auxiliary tool for clinical treatment.

学科与关键词

关键词
drug response signaturegemcitabineimmunitypancreatic ductal adenocarcinomasingle cell
相关
加载中…
  • An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma
    Xiao, Zhijun; Li, Jinyin; Yu, Qian; Zhou, Ting; Duan, Jingjing; Yang, Zhen; Liu, Cuicui*; Xu, Feng*Frontiers in Pharmacology, 2021, 12: 778294.被引 12
  • Acquired resistance of pancreatic cancer cells to cisplatin is multifactorial with cell context-dependent involvement of resistance genes
    Mezencev, R.; Matyunina, L. V.; Wagner, G. T.; McDonald, J. F.*Cancer Gene Therapy, 2016, 23(12): 446-453.被引 34
  • Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer
    Li, Yunguang; Tang, Shijie; Shi, Xiaohan; Lv, Jingwen; Wu, Xueyuan; Zhang, Yehan; Wang, Huan; He, Juan; Zhu, Yiqin; Ju, Yi; Zhang, Yajuan; Guo, Shiwei; Yang, Weiwei*; Yin, Huiyong*; Chen, Luonan*; Gao, Dong*; Jin, Gang*CELL REPORTS MEDICINE, 2023, 4(9): 101162.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Molecular Oncology
发表日期
2022-08
卷期
第 16 卷, 第 16 期
页码
3034-3051
DOI
10.1002/1878-0261.13279
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
Outstanding Youth Foundation of Heilongjiang Province of China [YQ2021H005]; HMU Marshal Initiative Funding [HMUMIF-21023]; National Natural Science Foundation of China [82003392]; Heilongjiang Provincial Natural Science Foundation of China [LH2019H068]

作者

  • L

    Liu, Kaidong (第一作者)

    harbin med univ

  • G

    Geng, Yiding

    harbin med univ

查看全部 12 位作者收起作者
  • W

    Wang, Linzhu

    harbin med univ

  • X

    Xu, Huanhuan

    harbin med univ

  • Z

    Zou, Min

    harbin med univ

  • L

    Li, Yawei

    harbin med univ

  • Z

    Zhao, Zhangxiang

    1

  • C

    Chen, Tingting

    harbin med univ

  • X

    Xu, Fengyan

    harbin med univ

  • S

    Sun, Liang

    harbin med univ

  • W

    Wu, Shuliang (通讯)

    harbin med univ

  • G

    Gu, Yunyan (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417